Human leukocyte antigen class I and II molecules on autologous dendritic cells (HLA-I/II on autologous DCs)

Human leukocyte antigen (HLA) class I and II molecules on autologous dendritic cells serve as the critical interface for initiating adaptive immune responses. HLA class I molecules (HLA-A, -B, -C) present endogenous peptides to CD8+ cytotoxic T-cells, while HLA class II molecules (HLA-DR, -DP, -DQ) present exogenous peptides to CD4+ helper T-cells (Source: NIH, StatPearls). In the context of immunotherapy, autologous dendritic cells are harvested from a patient, loaded with specific antigens (such as tumor-associated antigens), and re-infused to stimulate a targeted T-cell attack against cancer or infectious agents (Source: PubMed, PMID: 30634452). This platform is the basis for several cellular therapies, most notably Sipuleucel-T, which utilizes autologous antigen-presenting cells to treat prostate cancer (Source: FDA, Package Insert). The efficacy of these therapies depends on the successful processing and presentation of antigens by these HLA molecules to the patient's own T-cell repertoire (Source: Nature Reviews Immunology).

Other names

MHC class I and II on autologous dendritic cellsHLA-A/B/C and HLA-DR/DP/DQ on patient-derived dendritic cellsAutologous antigen-presenting cells expressing HLAMajor histocompatibility complex molecules on autologous DCs

Antigen presentation to T-cells via MHC-peptide complexes to induce a specific immune response against tumor-associated antigens or pathogens.